Why The Brain Matrix Alliance is needed?
By 2030 half of the worldwide economic impact of disability will be due specifically to brain-related disability. The global toll of brain disorders exceeds that of all other diseases
Brain Health: GLOBAL Emergency
- Brain Health universal definition is needed
- Less research than for cancer and heart conditions
- Slow translation of discoveries into practice (17years)
- No insurance reimbursement for treatments
- Existing brain clinicians need support to scale
- Legal therapeutic framework still evolving
- Fewer doctors specializing in brain health
- Delivery infrastructure not developed
More than 1 BILLION
people throughout the world are affected by some type of neurological disease.
1 in 3
people will develop a neurological disorder at some point in their life
According to WHO
and World Bank it is estimated that an additional 18 million health workers will be needed to provide adequate support by 2030 just for dementia
153 million people by 2050
are expected to be living with dementia worldwide, up from 57 million as reported by the Institute for Health Metrics and Evaluation
Neurological Incidences
are expected to soar as the population ages, due to neurodegenerative diseases striking primarily during mid- to late-life
Over the past 30 years
the rate of Parkinson’s and dementia incidences have more than doubled
Sources:
World Health Organization
Politico Europe, 26 April 2023
Alzheimer’s Disease International
Some of the biggest challenges facing brain health right now are defining what brain health means to everyone. The term brain health is wide-ranging: from mental health — anxiety, depression, bipolar disorder; neurological disorders such as Alzheimer’s disease; multiple sclerosis; stroke; brain and central nervous system cancers; encephalitis and meningitis. By listing just some of these conditions, the scale of the challenge is clear.
In addition to defining brain health, global efforts need data to inform patients, researchers, and the medical community to enable them to work together. Awareness by consumers, acceptance by physicians, insurance reimbursement and access ease are primary barriers impeding translation of neuroplasticity & epigenetic discoveries into clinical practice. Physicians and therapists are often reluctant to recommend neuroplasticity, longevity, psychedelic treatments for multiple reasons: it goes against medical school teachings, the supporting science is still building evidence-based studies at this development stage, and the physician-pharmaceutical ecosystem is part of the dynamics. And for the same reasons, insurance providers don’t typically reimburse for these treatments. Another challenge is that existing treatments are not always easy to access - they often require travel and repeated daily effort over multiple weeks or months to be effective. Without physician or dedicated word of mouth referrals and the lack of insurance reimbursement, patients are often unaware of these treatment options and are cautious about trying something unfamiliar.
The Brain Matrix Alliance (BMA) is tackling each of these barriers at the consumer, professional, and industry levels.
Subscribe to our newsletter
Get notified of updates and events by BMA directly to your inbox.